Mayara dos Santos Maia May

Dr. Mayara dos Santos Maia May


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2023 in Molecules
Verified
Journal Article
Open access
PDF file
MMMayara dos Santos Maia May
Mayara dos Santos Maia May
Francisco Mendonça JuniorFrancisco Mendonça Junior
Francisco Mendonça Junior
GRGabriela Cristina Soares Rodrigues
Gabriela Cristina Soares Rodrigues
ASAdriano Soares da Silva
Adriano Soares da Silva
NONiara Isis Pereira de Oliveira
Niara Isis Pereira de Oliveira
LUCIANA SCOTTILUCIANA SCOTTI
LUCIANA SCOTTI
Cancer is a multifactorial disease that continues to increase. Lignans are known to be important anticancer agents. However, due to the structural diversity of lignans, it is difficult to associate anticancer activity with a particular subclass. Therefore, the present study sought to evaluate the association of lignan subclasses with antitumor activity, considering the genetic profile of the variants of the selected targets. To do so, predictive models were built against the targets tyrosine-protein kinase ABL (ABL), epidermal growth factor receptor erbB1 (EGFR), histone deacetylase (HDAC), serine/threonine-protein kinase mTOR (mTOR) and poly [ADP-ribose] polymerase-1 (PARP1). Then, single nucleotide polymorphisms were mapped, target mutations were designed, and molecular docking was performed with the lignans with the best predicted biological activity. The results showed more anticancer activity in the dibenzocyclooctadiene, furofuran and aryltetralin subclasses. The lignans with the best predictive values of biological activity showed varying binding energy results in the presence of certain genetic variants.

16 June 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
MMMayara dos Santos Maia May
Mayara dos Santos Maia May
Francisco Mendonça JuniorFrancisco Mendonça Junior
Francisco Mendonça Junior
GRGabriela Cristina Soares Rodrigues
Gabriela Cristina Soares Rodrigues
ASAdriano Soares da Silva
Adriano Soares da Silva
NONiara Isis Pereira de Oliveira
Niara Isis Pereira de Oliveira
Marcus ScottiMarcus Scotti
Marcus Scotti
Cancer is a multifactorial disease that continues to increase. Lignans are known to be important anticancer agents. However, due to the structural diversity of lignans, it is difficult to associate anticancer activity with a particular subclass. Therefore, the present study sought to evaluate the association of lignan subclasses with antitumor activity, considering the genetic profile of the variants of the selected targets. For this, predictive models were built against the targets tyrosine-protein kinase ABL (ABL), epider-mal growth factor receptor erbB1 (EGFR), histone deacetylase (HDAC), Serine/threonine-protein kinase mTOR (mTOR) and Poly [ADP-ribose] polymerase-1 (PARP1). Then, mapped single nucleotide polymorphisms and designed target mutations, and performed molecular docking with the lignans with the best predicted biological activity. The results showed more anticancer activity in the dibenzocyclooctadiene, furofuran and aryltetralin subclasses. The lignans with the best predictive values of biological activity showed varying binding energy results in the presence of certain genetic variants.